Search

Your search keyword '"Faroux, R."' showing total 227 results
Start Over Author "Faroux, R."
227 results on '"Faroux, R."'

2. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

Author

Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., and Emile, J.-F.

Published
2020
Full Text
View/download PDF

3. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

Author

Zawadi, Mohamed-Ayman, Volet, Julien, Cavaglione, Gérard, Lepere, Céline, Rougier, Philippe, Zaanan, Aziz, Besson, Dominique, Fawzi, Kara Slimane, Adenis, Antoine, Gatineau-Sailliant, Gilles, Brezault, Catherine, Coriat, Romain, Tougeron, David, Hautefeuille, Vincent, Chone, Laurence, Molin, Yann, Seitz, Jean-François, Le Tallec, Véronique Jestin, Ben Abdelghani, Meher, Villing, Anne-Laure, Aouakli, Amar, Sebbagh, Virginie, Bedjaoui, Ahmed, Mitry, Emmanuel, Carola, Elisabeth, Boulat, Olivier, Queuniet, Anne-Marie, Capitain, Olivier, Jouve, Jean-Louis, Baumgaertner, Isabelle, Almaric, Françoise, Bonnetain, Franck, Subtil, Fabien, Aparicio, T., Bouché, O., Francois, E., Retornaz, F., Barbier, E., Taieb, J., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Bedenne, L., and Paillaud, E.

Published
2018
Full Text
View/download PDF

4. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Author

Aparicio, T., Bouché, O., Taieb, J., Maillard, E., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Paillaud, E., Retornaz, F., François, E., and Bedenne, L.

Published
2018
Full Text
View/download PDF

5. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Author

Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., and Schneider, M.

Published
2016
Full Text
View/download PDF

7. LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial

Author

Lepage, C., primary, Phelip, J.M., additional, Cany, L., additional, Barbier, E., additional, Manfredi, S., additional, Deguiral, P., additional, Faroux, R., additional, Baconnier, M., additional, Pezet, D., additional, Terrebonne, E., additional, Adenis, A., additional, Ben Abdelghani, M., additional, Ain, J.F., additional, Breysacher, G., additional, Benedetto, I. Boillot, additional, Pelaquier, A., additional, Lievre, A., additional, Puig, P. Laurent, additional, Bibeau, F., additional, and Bouche, O., additional

Published
2022
Full Text
View/download PDF

8. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)

Author

Metges, J. P., Lebot, M. A., Faroux, R., Riaud, F., Gamelin, E., Capitain, O., Guérin Meyer, V., Leynia, P., Douillard, J. Y., Senellart, H., Rochard, S., Louvigné, C., Campion, L., Dupuis, O., Grollier, C., Achour, N. A., Person, B., Raoul, J. L., Boucher, E., Bertrand, C., Ramée, J. F., Guivarch, L., Etienne, P. L., Roussel, S., Desclos, H., Julien, M. N., Labarre, M. I., Klein, V., Bessard, R., Stampfli, C., Royet, F., Faycal, J., Gouva, S., Le Bihan, G., Couturier, M., Gourlaouen, A., Bertholom, C., Porneuf, M., Jobard, E., Peguet, E., Grasset, D., Bouret, J. F., Bicheler, V., Ulvoas, A., Miglianico, L., Chouzenoux, C., Deguiral, P., Derenne, L., Martin, D., Langlet, P. Michel, Bodin, C., Rossi, V., Barré, S., Cojocarasu, O., Naveau Ploux, C., Vidal, A. M., Cumin, I., Egreteau, J., Brouard, A., Matysiak Budnik, T., Thomaré, P., Le Bris Michel, A. S., Piriou, G., Largeau, R., Elhannani, C., Crespeau, E., Suberville, F., Bourgeois, H., Riche, C., Lagadec, D. Déniel, Marhuenda, F., and Grudé, F.

Published
2014
Full Text
View/download PDF

10. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

Author

Conroy, T., primary, Hammel, P., additional, Turpin, A., additional, Belletier, C., additional, Wei, A., additional, Mitry, E., additional, Lopez, A., additional, Francois, E., additional, Artru, P., additional, Biagi, J., additional, Lecomte, T., additional, Assenat, E., additional, Faroux, R., additional, Ychou, M., additional, Bouche, O., additional, Lambert, A., additional, Monard, L., additional, Rat, P., additional, Castan, F., additional, and Bachet, J-B., additional

Published
2021
Full Text
View/download PDF

12. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

Author

Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J. L., Ychou, M., Legoux, J. L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F. R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., and de Gramont, A.

Published
2015
Full Text
View/download PDF

14. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis

Author

Blanc, J. (Jean-Frédéric) F. (F), Khemissa, F. (Faiza), Bronowicki, J. (Jean-Pierre) P. (P), Monterymard, C. (Carole), Perarnau, J. (Jean-Marc) M. (M), Bourgeois, V. (Vincent), Obled, S. (Stéphane), Abdelghani, M. (Meher) B. (Ben), Mabile-Archambeaud, I. (Isabelle), Faroux, R. (Roger), Seitz, J. (Jean-François) F. (F), Locher, C. (Christophe), Senellart, H. (Hélène), Villing, A. (Anne-Laure) L. (L), Audemar, F. (Franck), Costentin, C. (Charlotte), Deplanque, G. (Gaël), Manfredi, S. (Sylvain), Edeline, J. (Julien), and Habersetzer, F. (Francois)

Subjects
Sorafenib, medicine.medical_specialty, Cirrhosis, Population, Sciences du Vivant [q-bio]/Médecine humaine et pathologie, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Medicine, education, education.field_of_study, Hepatology, business.industry, medicine.disease, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, business, Pravastatin, medicine.drug
Abstract

BACKGROUND AND AIMS: There is limited data regarding the role for systemic treatment in patients with Hepatocellular Carcinoma with Child-Pugh B cirrhosis. METHODS: PRODIGE 21 was a multicentric prospective non-comparative randomized trial. Patients were randomized to receive sorafenib (Arm A), pravastatin (Arm B), sorafenib-pravastatin (Arm C) combination, or best supportive care (Arm D). Primary endpoint was time to progression (TTP), secondary endpoints included safety and overall survival (OS). RESULTS: 160 patients were randomized and 157 patients were included in the final analysis. 86% of patients were BCLC C and 55% had macrovascular invasion. The safety profiles of the drugs were as expected. Median TTP was 3.5, 2.8, 2.0 and 2.2 months in arms A, B, C and D, respectively, but analysis was limited by the number of patients deceased without radiological progression (59%). Median OS was similar between the four arms: 3.8 [95% CI: 2.4-6.5], 3.1 [95% CI: 1.9-4.3], 4.0 [95% CI: 3.2-5.5] and 3.5 months [95% CI: 2.2-5.4] in arms A, B, C and D, respectively. Median OS was 4.0 months [95% CI: 3.3-5.5] for patients treated with sorafenib, vs 2.9 months [95% CI: 2.2-3.9] for patients not treated with sorafenib. In patients with ALBI grade 1/2, median OS was 6.1 months [95% CI: 3.8-8.3] in patients treated with sorafenib vs 3.1 months [95% CI: 1.9-4.8] for patients not treated with sorafenib. CONCLUSION: In the overall Child-Pugh B population, neither sorafenib nor pravastatin seemed to provide benefit. In the ALBI grade 1/2 sub-population, our trial suggests potential benefit of sorafenib. CLINICAL TRIAL REGISTRATION: The study was referenced in clinicaltrials.gov (NCT01357486).

Published
2021

15. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Author

Hammel P., Kindler H. L., Reni M., Van Cutsem E., MacArulla T., Hall M. J., Park J. O., Hochhauser D., Arnold D., Oh D. -Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E. M., McGuinness D., Cui K. Y., Joo S., Yoo H. K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J. -L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J. -F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J. -P., Tougeron D., Walter T., Ettrich T., Hacker U. T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J. -W., Oh Park J., Wilmink H., Gallego R. A., Ogalla G. D., Velasco A. G., Cabanas E. G., Gomez Martin C., Ponce C. G., Saez B. L., Lopez R., Martin A. M., Pazo R., Pijaume C. P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D. A., Jeffrey Evans T. R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Hammel P., Kindler H.L., Reni M., Van Cutsem E., MacArulla T., Hall M.J., Park J.O., Hochhauser D., Arnold D., Oh D.-Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E.M., McGuinness D., Cui K.Y., Joo S., Yoo H.K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J.-L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J.-F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J.-P., Tougeron D., Walter T., Ettrich T., Hacker U.T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J.-W., Oh Park J., Wilmink H., Gallego R.A., Ogalla G.D., Velasco A.G., Cabanas E.G., Gomez Martin C., Ponce C.G., Saez B.L., Lopez R., Martin A.M., Pazo R., Pijaume C.P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D.A., Jeffrey Evans T.R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Institut Català de la Salut, [Hammel P] Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. [Kindler HL] Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA. [Reni M] Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology, Barcelona, Spain. [Hall MJ] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA, Vall d'Hebron Barcelona Hospital Campus, CCA - Cancer Treatment and Quality of Life, and Oncology

Subjects
Male, 0301 basic medicine, Oncology, medicine.medical_treatment, BRCA, pancreatic cancer, Disease, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Piperazines, Germline, Medicaments antineoplàstics, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Neoplasm Metastasis, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], BRCA1 Protein, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Middle Aged, Progression-Free Survival, humanities, 3. Good health, metastatic, health-related quality of life, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Poly(ADP-ribose) Polymerase Inhibitors, Placebo, olaparib, Olaparib, 03 medical and health sciences, Double-Blind Method, Metàstasi, Pancreatic cancer, Internal medicine, Gastrointestinal Tumors, medicine, Humans, Germ-Line Mutation, Aged, BRCA2 Protein, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], Chemotherapy, Pàncrees - Càncer, business.industry, BRCA mutation, Original Articles, medicine.disease, Pancreatic Neoplasms, Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], 030104 developmental biology, chemistry, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Quality of Life, Phthalazines, Neoplasm Recurrence, Local, business
Abstract

Qualitat de vida relacionada amb la salut; Olaparib; Càncer de pàncrees Calidad de vida relacionada con la salud; Olaparib, Cáncer de páncreas Health-related quality of life; Olaparib; Pancreatic cancer Background Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. Patients and methods Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. Results Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was

Published
2019

16. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer

Author

Mineur, L., primary, François, E., additional, Plassot, C., additional, Phelip, J. M., additional, Miglianico, L., additional, Dourthe, L. M., additional, Bonichon, N., additional, Moreau, L., additional, Guimbaud, R., additional, Smith, D., additional, Achille, E., additional, Hervé, R., additional, Bons, J. M., additional, Remy, S., additional, Faroux, R., additional, Villing, A. L., additional, Mahamat, A., additional, Rabbia, I., additional, Soulié, P., additional, Baumgaertner, I., additional, Mathé, N., additional, Vazquez, L., additional, and Boustany, R., additional

Published
2020
Full Text
View/download PDF

17. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

18. 444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers

Author

Legoux, J.L., primary, Faroux, R., additional, Barriere, N., additional, Le Malicot, K., additional, Tougeron, D., additional, Lorgis, V., additional, Guérin-Meyer, V., additional, Bourgeois, V., additional, Malka, D., additional, Aparicio, T., additional, Baconnier, M., additional, Lebrun-Ly, V., additional, Egreteau, J., additional, Akouz, F. Khemissa, additional, Lepage, C., additional, and Boige, V., additional

Published
2020
Full Text
View/download PDF

19. 443P First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study

Author

Gallois, C., primary, Hafliger, E., additional, Auclin, E., additional, Perret, A., additional, Artru, P., additional, Coutzac, C., additional, Turpin, A., additional, Pellat, A., additional, Randrian, V., additional, Basile, D., additional, Faroux, R., additional, Locher, C., additional, Hautefeuille, V., additional, Dubreuil, O., additional, Palmieri, L-J., additional, Dior, M., additional, and Taieb, J., additional

Published
2020
Full Text
View/download PDF

20. 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial

Author

Lepage, C., primary, Phelip, J.M., additional, Cany, L., additional, Barbier, E., additional, Manfredi, S., additional, Deguiral, P., additional, Faroux, R., additional, Baconnier, M., additional, Pezet, D., additional, Duchmann, J., additional, Terrebonne, E., additional, Adenis, A., additional, Benabdelghani, M., additional, Ain, J., additional, Breysacher, G., additional, Boillot-Benedetto, I., additional, Pelaquier, A., additional, Prost, P., additional, Lievre, A., additional, and Bouche, O., additional

Published
2020
Full Text
View/download PDF

21. Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’

Author

Pagès, F., primary, André, T., additional, Taieb, J., additional, Vernerey, D., additional, Henriques, J., additional, Borg, C., additional, Marliot, F., additional, Ben Jannet, R., additional, Louvet, C., additional, Mineur, L., additional, Bennouna, J., additional, Desrame, J., additional, Faroux, R., additional, Kirilovsky, A., additional, Duval, A., additional, Laurent-Puig, P., additional, Svrcek, M., additional, Hermitte, F., additional, Catteau, A., additional, Galon, J., additional, and Emile, J-F., additional

Published
2020
Full Text
View/download PDF

23. Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Author

Randrian, V., primary, Adenis, A., additional, Desrame, J., additional, Barbier, E., additional, Di Fiore, F., additional, Lievre, A., additional, Dahan, L., additional, Laurent-Puig, P., additional, Mineur, L., additional, Breysacher, G., additional, Roquin, G., additional, Louafi, S., additional, Lopez, A., additional, Louvet, C., additional, Borg, C., additional, Metges, J.-P., additional, Faroux, R., additional, Gaba, L., additional, Manfredi, S., additional, and Tougeron, D., additional

Published
2019
Full Text
View/download PDF

24. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

Author

Taieb, J., primary, Taly, V., additional, Vernerey, D., additional, Bourreau, C., additional, Bennouna, J., additional, Faroux, R., additional, Desrame, J., additional, Bouche, O., additional, Borg, C., additional, Egreteau, J., additional, Mineur, L., additional, Lepere, C., additional, Deplanque, G., additional, Mulot, C., additional, Louvet, C., additional, Mabro, M., additional, Ychou, M., additional, de Gramont, A., additional, Andre, T., additional, and Laurent-Puig, P., additional

Published
2019
Full Text
View/download PDF

25. Corrections to “Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results”

Author

Aparicio, T., primary, Bouché, O., additional, Taieb, J., additional, Maillard, E., additional, Kirscher, S., additional, Etienne, P -L, additional, Faroux, R., additional, Khemissa Akouz, F., additional, El Hajbi, F., additional, Locher, C., additional, Rinaldi, Y., additional, Lecomte, T., additional, Lavau-Denes, S., additional, Baconnier, M., additional, Oden-Gangloff, A., additional, Genet, D., additional, Paillaud, E., additional, Retornaz, F., additional, François, E., additional, and Bedenne, L., additional

Published
2018
Full Text
View/download PDF

26. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

Author

Aparicio, T., primary, Bouché, O., additional, Francois, E., additional, Retornaz, F., additional, Barbier, E., additional, Taieb, J., additional, Kirscher, S., additional, Etienne, P.-L., additional, Faroux, R., additional, Khemissa Akouz, F., additional, El Hajbi, F., additional, Locher, C., additional, Rinaldi, Y., additional, Lecomte, T., additional, Lavau-Denes, S., additional, Baconnier, M., additional, Oden-Gangloff, A., additional, Genet, D., additional, Bedenne, L., additional, Paillaud, E., additional, Zawadi, Mohamed-Ayman, additional, Volet, Julien, additional, Cavaglione, Gérard, additional, Lepere, Céline, additional, Rougier, Philippe, additional, Zaanan, Aziz, additional, Besson, Dominique, additional, Fawzi, Kara Slimane, additional, Adenis, Antoine, additional, Gatineau-Sailliant, Gilles, additional, Brezault, Catherine, additional, Coriat, Romain, additional, Tougeron, David, additional, Hautefeuille, Vincent, additional, Chone, Laurence, additional, Molin, Yann, additional, Seitz, Jean-François, additional, Le Tallec, Véronique Jestin, additional, Ben Abdelghani, Meher, additional, Villing, Anne-Laure, additional, Aouakli, Amar, additional, Sebbagh, Virginie, additional, Bedjaoui, Ahmed, additional, Mitry, Emmanuel, additional, Carola, Elisabeth, additional, Boulat, Olivier, additional, Queuniet, Anne-Marie, additional, Capitain, Olivier, additional, Jouve, Jean-Louis, additional, Baumgaertner, Isabelle, additional, Almaric, Françoise, additional, Bonnetain, Franck, additional, and Subtil, Fabien, additional

Published
2018
Full Text
View/download PDF

27. Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method

Author

Boisdron-Celle, M., primary, Metges, J., additional, Capitain, O., additional, Faroux, R., additional, Stampfli, C., additional, Ferec, M., additional, Laplaige, P., additional, Lecomte, T., additional, Matysiak-Budnik, T., additional, Senellart, H., additional, Campone, M., additional, Morel, A., additional, and Gamelin, E., additional

Published
2018
Full Text
View/download PDF

28. Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients

Author

Blanc, J.-F., primary, Khemissa, F., additional, Bronowicki, J.-P., additional, Monterymard, C., additional, Perarnau, J.-M., additional, Bourgeois, V., additional, Obled, S., additional, Abdelghani, M.B., additional, Mabile-Archambeaud, I., additional, Faroux, R., additional, Seitz, J.-F., additional, Locher, C., additional, Senellart, H., additional, Villing, A.-L., additional, Audemar, F., additional, Costentin, C., additional, Delplanque, G., additional, Manfredi, S., additional, and Edeline, J., additional

Published
2018
Full Text
View/download PDF

29. Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

Author

Taieb, J., primary, Bonnetain, F., additional, Mineur, L., additional, Bennouna, J., additional, Desrame, J., additional, Faroux, R., additional, Fratte, S., additional, Dauba, J., additional, Vernerey, D., additional, Louvet, C., additional, Lepere, C., additional, Dupuis, O., additional, Becouarn, Y., additional, Mabro, M., additional, Egreteau, J., additional, Bouche, O., additional, Deplanque, G., additional, Ychou, M., additional, de Gramont, A., additional, and André, T., additional

Published
2017
Full Text
View/download PDF

30. Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial

Author

Aparicio, T., primary, Bennouna, J., additional, Le Malicot, K., additional, Boige, V., additional, Taieb, J., additional, Bouche, O., additional, Francois, E., additional, Phelip, J-M., additional, Borel, C., additional, Faroux, R., additional, Dahan, L., additional, Bachet, J-B., additional, Egreteau, J., additional, Kaminsky-Forrett, M-C., additional, Gornet, J-M., additional, Cojocarasu, O., additional, Gasmi, M., additional, Guerin-Meyer, V., additional, Ghiringhelli, F., additional, and Lepage, C., additional

Published
2017
Full Text
View/download PDF

31. Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Author

Edeline, J., primary, Bonnetain, F., additional, Phelip, J-M., additional, Watelet, J., additional, Hammel, P., additional, Joly, J-P., additional, Benabdelghani, M., additional, Fartoux, L., additional, Bouhier-Leporrier, K., additional, Jouve, J-L., additional, Faroux, R., additional, Guerin-Meyer, V., additional, Assenat, E., additional, Seitz, J-F., additional, Malka, D., additional, Louvet, C., additional, Bertaut, A., additional, Juzyna, B., additional, Stanbury, T., additional, and Boucher, E., additional

Published
2017
Full Text
View/download PDF

32. A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)

Author

Hammel, P., primary, Bachet, J-B., additional, Portales, F., additional, Mineur, L., additional, Metges, J-P., additional, de la Fouchardiere, C., additional, Louvet, C., additional, El Hajbi, F., additional, Faroux, R., additional, Guimbaud, R., additional, Tougeron, D., additional, Volet, J., additional, Lecomte, T., additional, Tournigand, C., additional, Rebischung, C., additional, Berlier, W., additional, Gupta, A., additional, Cros, J., additional, André, T., additional, and El-Hariry, I., additional

Published
2017
Full Text
View/download PDF

34. 842TiP - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Author

Randrian, V., Adenis, A., Desrame, J., Barbier, E., Di Fiore, F., Lievre, A., Dahan, L., Laurent-Puig, P., Mineur, L., Breysacher, G., Roquin, G., Louafi, S., Lopez, A., Louvet, C., Borg, C., Metges, J.-P., Faroux, R., Gaba, L., Manfredi, S., and Tougeron, D.

Published
2019
Full Text
View/download PDF

35. PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)

Author

Legoux, J.L., primary, Le Malicot, K., additional, Faroux, R., additional, Boige, V., additional, Barriere, N., additional, Egreteau, J., additional, Rinaldi, Y., additional, Maillard, E., additional, Baconnier, M., additional, Lecaille, C., additional, Herrmann-Gandara, S., additional, Vimal, A., additional, Touchefeu, Y., additional, Raimbourg, J., additional, and Aparicio, T., additional

Published
2016
Full Text
View/download PDF

36. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Author

Lepage, C., primary, Phelip, J.-M., additional, Cany, L., additional, Maillard, E., additional, Lievre, A., additional, Chatellier, T., additional, Faroux, R., additional, Duchmann, J.-C., additional, Ben Abdelghani, M., additional, Breysacher, G., additional, Geoffroy, P., additional, Pere-Verge, D., additional, Pelaquier, A., additional, Pillon, D., additional, Ezenfis, J., additional, Rinaldi, Y., additional, Darut-Jouve, A., additional, Duluc, M., additional, Adenis, A., additional, and Bouché, O., additional

Published
2016
Full Text
View/download PDF

37. Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20

Author

Aparicio, T., primary, Bouché, O., additional, Francois, E., additional, Maillard, E., additional, Kirscher, S., additional, Taieb, J., additional, Etienne, P.-L., additional, Faroux, R., additional, Khemissa Akouz, F., additional, El Hajbi, F., additional, Locher, C., additional, Rinaldi, Y., additional, Lecomte, T., additional, Lavau-Denes, S., additional, Baconnier, M., additional, Oden-Gangloff, A., additional, Genet, D., additional, Paillaud, E., additional, Retornaz, F., additional, and Bedenne, L., additional

Published
2016
Full Text
View/download PDF

39. THU-151 - Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients

Author

Blanc, J.-F., Khemissa, F., Bronowicki, J.-P., Monterymard, C., Perarnau, J.-M., Bourgeois, V., Obled, S., Abdelghani, M.B., Mabile-Archambeaud, I., Faroux, R., Seitz, J.-F., Locher, C., Senellart, H., Villing, A.-L., Audemar, F., Costentin, C., Delplanque, G., Manfredi, S., and Edeline, J.

Published
2018
Full Text
View/download PDF

40. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting

Author

Tournoux-Facon, C., Paoletti, Xavier, J.C., Barbare, Bouché, O., Rougier, P., Dahan, L., Lombard-Bohas, C., Faroux, R., J.L., Raoul, Debenne, L., Bonnetain, F., Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

42. DOSE INTENSITY AND TOLERANCE IMPROVEMENT OF CETUXIMAB, IRINOTECAN, 5-FU AND FOLINIC ACID IN PATIENTS WITH METASTATIC CRC; A PHARMACOKINETIC AND PHARMACOGENETIC APPROACH

Author

Gamelin, E., Metges, J., Adenis, Antoine, Raoul, Jean-Luc, Lam, Y., Lecomte, T., Faroux, R., Luet, D., Masliah, C., Berger, V., Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, CRLCC Eugène Marquis (CRLCC), Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Paul Papin, CRLCC Paul Papin, Cambefort, Jeanne, Université de Lille-UNICANCER, and Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2008

43. LBA29 - Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Author

Edeline, J., Bonnetain, F., Phelip, J-M., Watelet, J., Hammel, P., Joly, J-P., Benabdelghani, M., Fartoux, L., Bouhier-Leporrier, K., Jouve, J-L., Faroux, R., Guerin-Meyer, V., Assenat, E., Seitz, J-F., Malka, D., Louvet, C., Bertaut, A., Juzyna, B., Stanbury, T., and Boucher, E.

Published
2017
Full Text
View/download PDF

47. Interim Analysis of Prodige 9, a Randomized Phase III Trial Comparing No Treatment to Bevacizumab Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer

Author

Aparicio, T., primary, Bennouna, J., additional, Le Malicot, K., additional, Ghiringhelli, F., additional, Boige, V., additional, Taieb, J., additional, Bouché, O., additional, Francois, E., additional, Phelip, J., additional, Borel, F., additional, Faroux, R., additional, Seitz, J., additional, Jacquot, S., additional, Genet, D., additional, and Lepage, C., additional

Published
2014
Full Text
View/download PDF

48. A Triple Combination Tailored Therapy (Folfiri-Cetuximab) for Safe Dose Intensification: A Multicenter Phase II Proof-Of-Concept Study.

Author

Capitain, O., primary, Metges, J.P., additional, Boisdron-Celle, M., additional, Adenis, A., additional, Raoul, J.L., additional, Lecomte, T., additional, Lam, Y., additional, Faroux, R., additional, Masliah, C., additional, Poirier, A.L., additional, Berger, V., additional, Morel, A., additional, and Gamelin, E., additional

Published
2014
Full Text
View/download PDF

49. Évaluation en pratique courante de l’association bevacizumab-FOLFIRI en première ligne chez des patients atteints d’un cancer colorectal métastatique non résécable traités en 2006: focus sur patients réséqués et oncogériatrie

Author

Metges, J. P., primary, Lebot, M. A., additional, Faroux, R., additional, Riaud, F., additional, Gamelin, E., additional, Capitain, O., additional, Guérin Meyer, V., additional, Leynia, P., additional, Douillard, J. Y., additional, Senellart, H., additional, Rochard, S., additional, Louvigné, C., additional, Campion, L., additional, Dupuis, O., additional, Grollier, C., additional, Achour, N. A., additional, Person, B., additional, Raoul, J. L., additional, Boucher, E., additional, Bertrand, C., additional, Ramée, J. F., additional, Guivarch, L., additional, Etienne, P. L., additional, Roussel, S., additional, Desclos, H., additional, Julien, M. N., additional, Labarre, M. I., additional, Klein, V., additional, Bessard, R., additional, Stampfli, C., additional, Royet, F., additional, Faycal, J., additional, Gouva, S., additional, Le Bihan, G., additional, Couturier, M., additional, Gourlaouen, A., additional, Bertholom, C., additional, Porneuf, M., additional, Jobard, E., additional, Peguet, E., additional, Grasset, D., additional, Bouret, J. F., additional, Bicheler, V., additional, Ulvoas, A., additional, Miglianico, L., additional, Chouzenoux, C., additional, Deguiral, P., additional, Derenne, L., additional, Martin, D., additional, Langlet, P. Michel, additional, Bodin, C., additional, Rossi, V., additional, Barré, S., additional, Cojocarasu, O., additional, Naveau Ploux, C., additional, Vidal, A. M., additional, Cumin, I., additional, Egreteau, J., additional, Brouard, A., additional, Matysiak Budnik, T., additional, Thomaré, P., additional, Le Bris Michel, A. S., additional, Piriou, G., additional, Largeau, R., additional, Elhannani, C., additional, Crespeau, E., additional, Suberville, F., additional, Bourgeois, H., additional, Riche, C., additional, Lagadec, D. Déniel, additional, Marhuenda, F., additional, and Grudé, F., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results